Publications by authors named "Kerstin Port"

Claim this Profile
T
TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.
Po-Chun Chen, Katja Deterding, Sophie Anna Engelskircher, Kerstin Port, Lisa Sandmann

Hepatology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life improves during antiviral therapy with bulevirtide.
Julia Carolin Eichholz, Christopher Dietz-Fricke, Simon Kristian Mrowietz, Katja Dinkelborg, Kerstin Port

Z Gastroenterol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.
Svenja Hardtke, Cihan Yurdaydin, Florin A Caruntu, Manuela G Curescu, Kendal Yalcin, Kerstin Port

J Viral Hepat· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples.
Lisa Sandmann, Birgit Bremer, Katja Deterding, Kerstin Port, Beatrix Gey

Hepatology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Julia Dietz, Christiana Graf, Christoph P Berg, Kerstin Port, Katja Deterding

JHEP Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.
Lisa Sandmann, Elisabetta Degasperi, Kerstin Port, Soo Aleman, Jeffrey J Wallin

Aliment Pharmacol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Olympia E Anastasiou, Florin A Caruntu, Manuela G Curescu, Kendal Yalcin, Ulus S Akarca, Kerstin Port

Liver Int· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Katja Dinkelborg, Julia Kahlhöfer, Petra Dörge, Cihan Yurdaydin, Svenja Hardtke, Kerstin Port

Liver Int· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.
Katja Deterding, Chengjian Xu, Kerstin Port, Christopher Dietz-Fricke, Jiang Xun

J Viral Hepat· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites.
Tammo L Tergast, Marie Griemsmann, Lena Stockhoff, Kerstin Port, Benjamin Heidrich

JAMA Netw Open· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
Lisa Sandmann, Katja Deterding, Birgit Bremer, Kerstin Port, Markus Cornberg

J Viral Hepat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, Münevver Demir, Hartmut H Schmidt, Kerstin Port

JHEP Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, Antje Blank, Natalia Voronkova, Kerstin Port

Lancet Infect Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C.
Tanvi Khera, Yanqin Du, Daniel Todt, Katja Deterding, Benedikt Strunz, Kerstin Port

J Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatment.
Yanqin Du, Tanvi Khera, Benedikt Strunz, Katja Deterding, Daniel Todt, Kerstin Port

Eur J Immunol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance.
Amare Aregay, Bastian Engel, Kerstin Port, Florian W R Vondran, Birgit Bremer

Liver Transpl· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients.
Solomon Owusu Sekyere, Kerstin Port, Katja Deterding, Markus Cornberg, Heiner Wedemeyer

United European Gastroenterol J· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort.
Antoaneta A Markova, Katja Deterding, Kerstin Port, Heike Bantel, Michael P Manns

Eur J Gastroenterol Hepatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.
Benjamin Schulte, Maximilian Wübbolding, Fiona Marra, Kerstin Port, Michael P Manns

Open Forum Infect Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis.
Friederike Ebel, Katja Deterding, Kerstin Port, Bernhard Schlevogt, Michael P Manns

Aliment Pharmacol Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Amare Aregay, Solomon Owusu Sekyere, Katja Deterding, Kerstin Port, Julia Dietz

J Hepatol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Heiner Wedemeyer, Cihan Yurdaydin, Svenja Hardtke, Florin Alexandru Caruntu, Manuela G Curescu, Kerstin Port

Lancet Infect Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated low-flow ascites pump in a real-world setting: complications and outcomes.
Philipp Solbach, Christoph Höner Zu Siederdissen, Freya Wellhöner, Nicolas Richter, Benjamin Heidrich, Port Kerstin

Eur J Gastroenterol Hepatol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?
Katharina L Hupa, Katja Deterding, Kerstin Port, Markus Kimmann, Michael P Manns

J Hepatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up.
Bernhard Schlevogt, Katja Deterding, Kerstin Port, Christoph Höner Zu Siederdissen, Lisa Sollik

Z Gastroenterol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis